Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy

2020 ◽  
pp. 1421-1454
Author(s):  
Kim Margolin ◽  
Michael Davies ◽  
Harriet Kluger ◽  
Hussein Tawbi
Keyword(s):  
Brain Metastases ◽  
Systemic Therapy ◽  
Unique Biology ◽  
Melanoma Brain Metastases

Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy

2019 ◽  
pp. 1-34
Author(s):  
Kim Margolin ◽  
Michael Davies ◽  
Harriet Kluger ◽  
Hussein Tawbi
Keyword(s):  
Brain Metastases ◽  
Systemic Therapy ◽  
Unique Biology ◽  
Melanoma Brain Metastases

Abstract PO-073: Mutational status and clinical outcomes following systemic therapy and focal radiation for melanoma brain metastases

2021 ◽  
Author(s):  
Harish N. Vasudevan ◽  
Matthew S. Susko ◽  
Lijun Ma ◽  
Jean L. Nakamura ◽  
David R. Raleigh ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Clinical Outcomes ◽  
Systemic Therapy ◽  
Mutational Status ◽  
Melanoma Brain Metastases

New Era in the Management of Melanoma Brain Metastases

2018 ◽  
pp. 741-750 ◽  
Author(s):  
Hussein A. Tawbi ◽  
Celine Boutros ◽  
David Kok ◽  
Caroline Robert ◽  
Grant McArthur
Keyword(s):  
Brain Metastases ◽  
Systemic Therapy ◽  
Single Agent ◽  
Local Treatment ◽  
New Era ◽  
Therapeutic Modalities ◽  
Melanoma Brain Metastases ◽  
Extracranial Disease ◽  
Induce Response ◽  
The Impact

The remarkable advances in the systemic therapy of metastatic melanoma have now extended the 1-year overall survival rate from 25% to nearing 85%. Systemic treatment in the form of BRAF-targeted therapy and immunotherapy is slowly but surely proving its efficacy in the treatment of metatstatic brain metastases (MBM). Single-agent BRAF inhibitors provide an intracranial response rate of 25% to 40%, whereas the combination of BRAFi/MEKi leads to responses in up to 58%. However, the durability of responses induced by BRAFi/MEKi seems to be even shorter than in extracranial disease. On the other hand, single-agent ipilimumab provides comparable clinical benefit in MBMs as it does in extracranial metastases. Single-agent PD-1 anitbodies induce response rates of approximately 20%, and those responses appear durable. Similarly the combination of CTLA-4+ PD-1 antibodies induces durable responses at an impressive rate of 55% and is safe to administer. Although the local treatment approaches with radiation and surgery remain important and are critically needed in the management of MBM, systemic therapy offers a new dimension that can augment the impact of those therapies and come at a potentially lower cost of neurocognitive impairment. Considerations for combining those modalities are direly needed, in addition to considering novel systemic combinations that target mechanisms specific to MBM. In this report, we will discuss the underlying biology of melanoma brain metastases, the clinical outcomes from recent clinical trials of targeted and immunotherapy, and their impact on clinical practice in the context of existing local therapeutic modalities.

Outcomes Of Systemic Therapy With Or Without Focal Radiotherapy Following Resection Of Melanoma Brain Metastases

2020 ◽  
Vol 108 (3) ◽  
pp. e706
Author(s):  
M.S. Susko ◽  
H. Vasudevan ◽  
J.L. Nakamura ◽  
D. Raleigh ◽  
L. Boreta ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Systemic Therapy ◽  
Melanoma Brain Metastases

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy

2018 ◽  
Vol 31 (4) ◽  
pp. 509-515 ◽  
Author(s):  
Martin Tio ◽  
Xuan Wang ◽  
Matteo S. Carlino ◽  
Brindha Shivalingam ◽  
Gerald B. Fogarty ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Brain Metastases ◽  
Systemic Therapy ◽  
Melanoma Brain Metastases

scholarly journals Melanoma brain metastases: the outcome of whole brain radiation therapy in the era of effective systemic therapy

2021 ◽  
Vol 0 ◽  
pp. 0-0
Author(s):  
Cora Waldstein ◽  
Wei Wang ◽  
Serigne Lo ◽  
Brindha Shivalingam ◽  
Gerald B. Fogarty ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Brain Metastases ◽  
Systemic Therapy ◽  
Whole Brain Radiation Therapy ◽  
Whole Brain ◽  
Whole Brain Radiation ◽  
Melanoma Brain Metastases ◽  
Brain Radiation

scholarly journals Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases

2019 ◽  
Vol 110 ◽  
pp. 11-20 ◽  
Author(s):  
Ricarda Rauschenberg ◽  
Johannes Bruns ◽  
Julia Brütting ◽  
Dirk Daubner ◽  
Fabian Lohaus ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Systemic Therapy ◽  
Melanoma Brain Metastases ◽  
Treatment Sequencing
Sign in / Sign up

Export Citation Format

Share Document